Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Chemotherapy as Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
NCT05880082Phase 2Completed
- Start
- Jan 2023
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC). Primary endpoints: Objective Response Rate at 6 months and Major Pathological Response Rate. Started Jan 2023; status: completed.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05880082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05880082.